Tesaro Biopharmaceuticals
135 Clarendon Street #14R
Boston
Massachusetts
02116
United States
Website: http://tesarobio.com/
Email: contact@tesarobio.com
49 articles with Tesaro Biopharmaceuticals
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Ac...
2/8/2019
Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation. -
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.
-
The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.
-
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
-
Impact Therapeutics, headquartered in Nanjing, China, completed a Series C financing round worth $30 million. The round was led by Decheng Capital with participating from Lilly Asian Ventures (LAV).
-
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
-
BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
-
Imara Strengthens Clinical Development Team with Key Appointments
5/30/2018
Imara Inc. today announced additions to its clinical development team with the appointments of Joe Datt, M.D., as Senior Vice President, Clinical Development, and Siddharth Parulkar as Head, Global Clinical Operations.
-
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
5/24/2018
Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.
-
Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the...
-
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.
-
A Biotech Binary Event Playbook: How To Play Clovis Oncology And Tesaro Ahead Of Label Decision
8/9/2017
-
Not-Yet Sold Tesaro Bags $340 Million Cancer Deal With Pharma Giant Takeda
7/28/2017
-
Will Tesaro Be The Focus Of The Next Biotech Bidding War?
6/14/2017
-
Why Sought-After Tesaro's Rumored Sale Could Bring in $200 Per Share
2/13/2017
-
Massachusetts' Tesaro Being Wooed by Multiple Suitors
2/10/2017
-
Clinigen Release: Company Initiates U.S. Managed Access Program For Tesaro’s Niraparib For Patients With Ovarian Cancer
1/17/2017
-
What's PARP? Meet Two of Biotech's Newest M&A Targets: Tesaro and Clovis Oncology
9/16/2016